ArticleJournal of pharmacy & bioallied sciences2024
Evaluation of Maxibloc Bone Grafts Biocompatibility and Osteoconductivity: An Animal Study.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Alveolar bone resorption poses a significant challenge in rehabilitating edentulous patients. Ridge augmentation materials can stimulate bone growth in deficient areas. Aim: To evaluate the biocompatibility and osteoconductivity of maxibloc bone grafts in rabbits. Materials and Methods: Maxibloc was packed into bony voids created surgically in the mandible and femur of rabbits, which were sacrificed at the fourth, eighth, and twelfth weeks. Radiography and histopathology evaluations assessed the osteoconductivity; hematology and toxicology evaluations assessed the biocompatibility of maxibloc. Results: Radiography revealed bone formation and homogenization without osteolysis. Histopathology revealed new bone formation with osteoblasts, fibrous and collagen tissue, cartilage formation, and no foreign body reaction or inflammation. Hematology revealed stable hemoglobin concentration, white blood cell count, eosinophil count, and absence of leucocytosis. Toxicology revealed elevated mortality rates at higher doses, whereas lower doses were safe. Animals exhibited no signs of systemic toxicity or behavioral changes. Conclusions: Maxibloc has demonstrated biocompatibility and osteoconductivity, presenting as a promising alloplastic bone graft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.